ANRO
Price
$15.54
Change
+$0.79 (+5.36%)
Updated
Nov 19 closing price
Capitalization
482.77M
Intraday BUY SELL Signals
NUVL
Price
$107.13
Change
+$2.89 (+2.77%)
Updated
Nov 19 closing price
Capitalization
7.78B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANRO vs NUVL

Header iconANRO vs NUVL Comparison
Open Charts ANRO vs NUVLBanner chart's image
Alto Neuroscience
Price$15.54
Change+$0.79 (+5.36%)
Volume$518.57K
Capitalization482.77M
Nuvalent
Price$107.13
Change+$2.89 (+2.77%)
Volume$2.17M
Capitalization7.78B
ANRO vs NUVL Comparison Chart in %
ANRO
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ANRO vs. NUVL commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Hold and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ANRO: $15.54 vs. NUVL: $107.06)
Brand notoriety: ANRO and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 25% vs. NUVL: 385%
Market capitalization -- ANRO: $482.77M vs. NUVL: $7.78B
ANRO [@Biotechnology] is valued at $482.77M. NUVL’s [@Biotechnology] market capitalization is $7.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANRO and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • ANRO’s TA Score: 4 bullish, 4 bearish.
  • NUVL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ANRO and NUVL are a good buy in the short-term.

Price Growth

ANRO (@Biotechnology) experienced а +9.44% price change this week, while NUVL (@Biotechnology) price change was +10.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($7.78B) has a higher market cap than ANRO($483M). ANRO YTD gains are higher at: 267.376 vs. NUVL (36.765). ANRO has higher annual earnings (EBITDA): -62.3M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. ANRO (148M). ANRO (0) and NUVL (0) have equivalent revenues.
ANRONUVLANRO / NUVL
Capitalization483M7.78B6%
EBITDA-62.3M-398.38M16%
Gain YTD267.37636.765727%
P/E RatioN/AN/A-
Revenue00-
Total Cash148M943M16%
Total Debt27.3MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ANRONUVL
RSI
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 17 days ago
86%
Bearish Trend 11 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ANRO
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYAVX74.74N/A
N/A
Rydex S&P MidCap 400 Pure Value H
FRIRX12.18N/A
N/A
Fidelity Advisor Real Estate Income I
FGFRX44.96N/A
N/A
Federated Hermes Intl Leaders R
SUSYX14.86N/A
N/A
SEI US Managed Volatility Y (SIMT)
PMVEX26.53N/A
N/A
PGIM Quant Solutions Mid-Cap Val R2

ANRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with IMTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then IMTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
+5.36%
IMTX - ANRO
36%
Loosely correlated
N/A
NUVL - ANRO
36%
Loosely correlated
+2.71%
NEVPF - ANRO
35%
Loosely correlated
N/A
BEAM - ANRO
34%
Loosely correlated
-4.24%
IPSC - ANRO
33%
Loosely correlated
+4.82%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.71%
RVMD - NUVL
60%
Loosely correlated
-0.04%
XNCR - NUVL
60%
Loosely correlated
-1.62%
XENE - NUVL
58%
Loosely correlated
+0.15%
IDYA - NUVL
58%
Loosely correlated
-1.72%
VRDN - NUVL
56%
Loosely correlated
+0.31%
More